-
4m 31s
-
3m 44sPart 1 | Session 2 Influence of Pathophysiological Patterns of CAD on PCI
-
5m 19sPart 1 | Session 3 Ancillary SMART Trial Analyses
-
3m 59sPart 1 | Session 4 Impact of Diabetes Severity After Abluminus DES+ Stent: ABILITY
-
4m 6s
-
26m 48sPart 1 | Session 6 1M DAPT Followed by 5M Ticagrelor Monotherapy in ACS with DCB: CAGEFREE II
-
26m 3sPart 2 | Session 1 View from the Thoraxcenter: What's Hot at EuroPCR 24?
-
18m 29sPart 2 | Session 2 View from the Thoraxcenter: EuroPCR 24 Wrap Up - Part 1
-
4m 13sPart 3 | Session 1 5 Trials That Will Change My Practice With Dr Mirvat Alasnag
EuroPCR 2024 - We are joined by Dr Bernardo Cortese (Ospedale Fate bene Fratelli, IT) for a concise and insightful summary of the late-breaking trials that are expected to have an impact on structural heart disease care.
Trials covered in detail include:
- LANDMARK
- ABILITY
- CAGEFREE II
- PICCOLETO VI
Recorded remotely onsite at EuroPCR 2024, Paris
Our regular review series View From the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) dives deep into the late-breaking trials of EuroPCR 2023, spotlighting the impactful data.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
Hear commentary on the practice-changing trials of EuroPCR 2024 from selected faculty in our Highlights Reviews.
More from this programme
Faculty Biographies
Bernardo Cortese
Dr Bernardo Cortese is Consultant Interventional Cardiologist for coronary and structural heart disease at the Columbus Clinic in Milano, and the Vercelli Hospital in Italy. He is the CEO of the DCB Academy, and Director of Cardiology at Clinical San Carlo in Milano.
Comments